Human Zoster Immunoglobulin, solution for intramuscular injection
Consumer Medicine Information
What is in this leaflet
This leaflet answers some common questions about Zoster Immunoglobulin-VF. It does not contain complete information about Zoster Immunoglobulin-VF. It does not take the place of talking to your doctor.
If you have any concerns about using this medicine, ask your doctor. Follow your doctor’s advice even if it is different from what this leaflet says.
Please read this leaflet carefully and keep it for future reference.
The information in this leaflet is subject to change. Please check with your doctor whether there is any new information about this medicine that you should know since you were last treated.
What Zoster Immunoglobulin-VF is used for
Zoster Immunoglobulin-VF is prepared from blood obtained from voluntary donors. Zoster Immunoglobulin-VF contains protein substances called antibodies which can provide protection against the virus causing chickenpox and shingles. It is used for the prevention of chickenpox and shingles in people who are susceptible to virus infection and who come into contact with an infected person. It is particularly given to those whose ability to fight infection is weakened.
Ask your doctor if you have any questions about why Zoster Immunoglobulin-VF has been prescribed for you. Your doctor will have assessed the risks and benefits associated with the use of this product for you.
Before you are given Zoster Immunoglobulin-VF
Zoster Immunoglobulin-VF must not be used if you have a history of allergy to this product. Tell your doctor if you have allergies to any other medicines or if you have ever had an allergic reaction to an injection.
Tell your doctor also if you:
- have previously been advised that you have immunoglobulin A (IgA) deficiency
- are taking or using any other medicines. These include medicines bought from pharmacies, supermarkets and health food stores.
- suffer from a blood disorder or blood clotting problem
- have had any vaccination during the last two weeks
- have any other medical conditions.
Pregnant or lactating women should discuss use of Zoster Immunoglobulin-VF with their doctor.
About blood products
This product is made from human plasma obtained from voluntary donors. When products are made from human blood and injected into you, it is possible that viruses or other substances could be present in the product and cause an illness. These could be viruses such as hepatitis, human immunodeficiency virus (HIV), or human parvovirus B19 and theoretically the Creutzfeldt-Jakob Disease (CJD) agent. There could also be other infectious agents some of which may not yet have been discovered.
To reduce the risk of this happening, extra steps are taken when manufacturing this product. Strict controls are applied to the selection of blood donors and donations. The product is specially treated to remove and kill certain viruses. These special treatments are considered effective against viruses known as enveloped viruses such as HIV, hepatitis B virus and hepatitis C virus, and the non-enveloped viruses, hepatitis A virus and human parvovirus B19. Additionally, the product contains specific antibodies which can provide some protection against human parvovirus B19. Despite these measures, the risk of viral and other agent’s infectivity cannot be totally eliminated.
Vaccines are available against some of these viruses and your doctor will be able to help you decide whether it is worthwhile having any of those vaccines.
Please discuss the risks and benefits of this product with your doctor.
How to use Zoster Immunoglobulin-VF
Your doctor will determine the dose(s) of Zoster Immunoglobulin-VF that you are to receive. Your doctor will give you the injection. It will be injected into the muscle. If a large volume of product is required, you may receive more than one injection.
Along with their intended effects, medicines may cause some unwanted effects, which can sometimes be serious. Furthermore, individual patients may react differently to the same dose of the same medicine. This applies to Zoster Immunoglobulin-VF.
Reactions are very uncommon after injection with Zoster Immunoglobulin-VF. However, some pain, redness and stiffness may be apparent at the injection site. This may occur after any large injection into a muscle.
Occasionally mild fever, chills, drowsiness or discomfort may be felt and an itchy rash may develop.
If any of these effects are severe, or if you are worried about any other symptoms after the injection, consult your doctor.
Zoster Immunoglobulin-VF can interfere with some live vaccines (e.g. measles and polio), even up to three months later. Advise your doctor if you are to receive other vaccines within three months of receiving Zoster Immunoglobulin-VF.
The consequences of overdosage are not known.
Storing Zoster Immunoglobulin-VF
Store at 2°C to 8°C (Refrigerate. Do not freeze). Protect from light.
Do not use after the expiry date shown on the label.
Zoster Immunoglobulin-VF can only be obtained on a doctor’s prescription. This leaflet does not contain the complete information about Zoster Immunoglobulin-VF. If you require further information about Zoster Immunoglobulin-VF and your treatment generally, or if you have any questions or are not sure about something in this leaflet, consult your doctor.
What it looks like
Zoster Immunoglobulin-VF is a clear, colourless, viscous (thick) solution which may be slightly shiny. It is available in glass bottles.
Each bottle of Zoster Immunoglobulin-VF is a sterile solution containing 160 mg/mL blood proteins of which at least 98% is immunoglobulins. It also contains 22.5 mg/mL glycine.
NOTE: Supplies of suitable plasma for the production of Zoster Immunoglobulin-VF are scarce. If you are recovering from shingles or chickenpox you are urged to enrol as a voluntary blood donor.
Zoster Immunoglobulin-VF is manufactured in Australia by:
CSL Behring (Australia) Pty Ltd
ABN 48 160 734 761
189-209 Camp Road
Broadmeadows VIC 3047
Australian Red Cross Blood Service
Date of most recent amendment
Australian Register Number:
AUST R 61219
Published by MIMS December 2014